Moderna sign COVID-19 vaccine production deal with South Korea's Samsung Biologics
23 May, 2021
Moderna said on Saturday (May 22) it has entered into an arrangement with Samsung Biologics, a deal which will permit the South Korean biopharmaceutical firm to produce the US company's mRNA vaccine.
Moderna intends to provide these vaccines to market segments outside of the United States starting in the 3rd one fourth of 2021, it said in a press release.
The firm also signed two memoranda of understanding (MOU) with South Korea's government, one with Korea National Institute of Health (KNIH) and another with Ministry of Trade and Industry and Energy of the Republic of Korea (MOTIE).
South Korea has secured usage of 40 million doses of Moderna's COVID-19 vaccine, Moderna said.
"We will continue steadily to explore alternatives for establishing potential local manufacturing prospects in South Korea," Moderna's LEADER Stéphane Bancel said.
Source: